Tesamorelin vs ipamorelin:
GHRH analog vs ghrelin mimetic.

The central difference between tesamorelin and ipamorelin is which receptor they activate to trigger GH release. Growth hormone secretion from pituitary somatotroph cells is regulated by two separate stimulatory pathways that work in parallel, and each peptide targets one of them.

Tesamorelin and the GHRH pathway. Tesamorelin is a structural analog of growth hormone–releasing hormone (GHRH), the hypothalamic peptide that naturally regulates GH secretion. It binds the GHRH receptor (GHRH-R), a G-protein-coupled receptor expressed on pituitary somatotroph cells. Activation of GHRH-R increases intracellular cyclic AMP (cAMP) and triggers both the synthesis of new GH and the release of stored GH into circulation. This is the primary pathway by which the hypothalamus regulates adult GH pulsatility.

Ipamorelin and the ghrelin pathway. Ipamorelin is a ghrelin receptor agonist — a synthetic peptide mimetic of the hormone ghrelin, which is primarily produced in the stomach but also acts on pituitary cells. Ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a), a different G-protein-coupled receptor than GHRH-R. GHS-R1a activation works through a phospholipase C / inositol trisphosphate (IP3) pathway rather than the cAMP pathway used by GHRH-R, but the downstream effect is the same: release of stored GH into circulation.

Because the two receptors use different signaling cascades and are not redundant with each other, simultaneous activation of both pathways produces a larger GH pulse than activation of either alone. This is the mechanistic basis for why tesamorelin and ipamorelin are commonly stacked — the two peptides are genuinely complementary, amplifying each other rather than competing for the same receptor pool. For detail on the stack, see the tesamorelin and ipamorelin stack guide.

Tesamorelin and ipamorelin are dramatically different in size and chemistry, reflecting the different receptor targets.

Tesamorelin is a large peptide — 44 amino acids, molecular weight approximately 5,136 daltons — that preserves the full structure of native human GHRH with a trans-3-hexenoyl modification at the N-terminal tyrosine. The entire tesamorelin sequence is evolutionarily optimized for binding GHRH-R, which is itself a large receptor that requires substantial binding surface area to activate.

Ipamorelin is a small synthetic pentapeptide — just 5 amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2), molecular weight approximately 712 daltons. The small size reflects the different receptor structure of GHS-R1a, which binds ghrelin at a more compact site. Ipamorelin was engineered specifically to activate GHS-R1a with high selectivity while minimizing activation of related receptors that can cause unwanted hormonal effects.

Both peptides are administered by subcutaneous injection (neither is orally bioavailable). Ipamorelin has a shorter plasma half-life of approximately 2 hours and produces a discrete GH pulse similar in duration to tesamorelin. Both peptides clear cleanly with no active metabolites and minimal drug-drug interaction concerns.

A major clinical difference between tesamorelin and ipamorelin is their hormonal selectivity — specifically, whether they affect cortisol and prolactin levels in addition to growth hormone.

Tesamorelin is highly selective for GH release. Activation of GHRH-R does not meaningfully affect cortisol or prolactin secretion at clinical doses. This is because GHRH-R signaling is specific to somatotroph cells and does not substantially cross-activate the hypothalamic-pituitary-adrenal or lactotroph pathways.

Ipamorelin is one of the most GH-selective ghrelin receptor agonists ever developed, specifically because it was engineered to minimize cortisol and prolactin elevation. Earlier-generation growth hormone secretagogues (GHS) like GHRP-6 and GHRP-2 are also ghrelin receptor agonists but activate GHS-R1a with less selectivity, producing significant cortisol and prolactin increases that can cause unwanted side effects (increased appetite, fatigue, mood changes, lactation in sensitive patients). Ipamorelin was designed to avoid these off-target effects, and clinical data shows minimal cortisol or prolactin elevation at standard doses.

This selectivity makes ipamorelin a cleaner GHS choice than earlier GHRPs and comparable to tesamorelin in terms of limiting off-target hormonal effects. Patients concerned about cortisol elevation — particularly those on HPA-axis-sensitive protocols or with existing adrenal considerations — can use either tesamorelin or ipamorelin without meaningful cortisol impact. This is one reason both peptides are preferred over older GHS compounds in modern protocols.

Tesamorelin has substantial Phase III clinical trial data anchored in the Falutz studies (NEJM 2007 and 2010) establishing 15–20% visceral fat reduction over 26–52 weeks, and the Stanley JAMA 2014 study showing 32% liver fat reduction in NAFLD over 12 months. These are randomized, placebo-controlled trials with imaging-based endpoints published in top-tier medical journals.

Ipamorelin's clinical data is considerably thinner. Ipamorelin has been studied in smaller trials primarily focused on safety, pharmacokinetics, and effects on postoperative ileus (reduced gut motility after surgery), where GHS-R1a activation accelerates gastric emptying. A 2013 trial published in the Journal of Parenteral and Enteral Nutrition investigated ipamorelin for postoperative ileus, and multiple Phase 2 studies have examined cancer cachexia applications. However, there is no Phase III body composition data for ipamorelin comparable to the tesamorelin VAT reduction evidence.

This doesn't mean ipamorelin doesn't produce body composition effects. The mechanism — pulsatile GH release — is the same as tesamorelin, and smaller studies and clinical experience support IGF-1 elevation, improved sleep quality, and modest body composition changes from ipamorelin monotherapy. But for the specific outcome of measurable visceral fat reduction at a quantifiable magnitude, tesamorelin's evidence base is stronger. Patients whose primary goal is VAT reduction have more direct clinical support for tesamorelin; patients with broader GH-support goals have reasonable evidence for either peptide.

Both peptides share the same general category of side effects because both elevate GH and IGF-1 through (different) pituitary pathways. Injection site reactions, mild joint aching, occasional peripheral edema, and modest glucose tolerance changes are common to both. The difference is magnitude and some pathway-specific effects.

Tesamorelin tends to produce more pronounced musculoskeletal effects (arthralgia in 13% of patients, peripheral edema in 8–10%) because it produces a larger cumulative GH pulse at typical doses. Injection site reactions occur in 20–30% of tesamorelin patients. Full tesamorelin side effect data is documented in the tesamorelin side effects guide.

Ipamorelin tends to have a milder side effect profile. Injection site reactions occur but at lower frequency. Arthralgia and edema are less common. The most distinctive ipamorelin-specific effect is a mild increase in hunger in the first hours after injection — a direct consequence of ghrelin receptor activation (ghrelin is the "hunger hormone"). This effect is typically modest because ipamorelin has high GH selectivity and doesn't strongly activate the central appetite pathways that native ghrelin does, but patients sensitive to appetite modulation may notice it.

Both peptides share the same contraindications — active malignancy, pregnancy, pituitary disease, and critical illness. Neither peptide has emerged with new safety signals in post-marketing data or extended use. For patients who find tesamorelin's side effect burden significant, switching to ipamorelin monotherapy or downshifting to a milder protocol is a reasonable adjustment.

The tesamorelin vs ipamorelin choice depends on the specific goal and the weight placed on clinical evidence vs mechanism vs tolerability.

Choose tesamorelin if: primary goal is visceral fat reduction with a clinical-grade evidence base, NAFLD or fatty liver is a concern, maximum GH pulse amplitude from a single peptide is preferred, and the FDA-approved status carries weight in the decision. Tesamorelin is the correct choice when magnitude and evidence matter most.

Choose ipamorelin if: primary goal is general GH support and IGF-1 elevation rather than targeted visceral fat reduction, tolerability of higher-magnitude GH effects is a concern, cost is a major factor (ipamorelin is substantially cheaper than tesamorelin), or multiple daily doses matches the desired protocol pattern better than single daily dosing.

Choose both (stack) if: you want the maximum GH pulse amplitude possible from peptide therapy. The tesamorelin and ipamorelin stack combines GHRH-R activation with GHS-R1a activation to produce a larger cumulative GH pulse than either monotherapy. This is the approach used when maximizing body composition response while maintaining the favorable selectivity profile of both peptides.

Consider sermorelin as a gentler alternative: for patients who want the GHRH pathway but with milder effect than tesamorelin, sermorelin is a shorter, less potent GHRH fragment. See the tesamorelin vs sermorelin comparison.